Status
Active, not recruiting
Phase
N/A
Study type
Observational
Enrollment
105
Sex
Women only
Ages
Adults (Child, Adult, Older Adult)
Primary completion
2026-07-31
Last update
2026-03-06

What this trial studies

This study is for women in Germany who are going through menopause. They have symptoms including hot flashes and night sweats (also called vasomotor symptoms). Their doctor has decided to give them fezolinetant tablets to help treat these symptoms. Fezolinetant tablets do not contain hormones.

Conditions in scope

  • Hot Flashes

Interventions

  • Fezolinetant (Drug) — Oral

Who can join

Women only · Adults (Child, Adult, Older Adult)

Inclusion criteria

  • Participant has been prescribed fezolinetant for the treatment of VMS associated with menopause according to routine clinical practice
  • Participant is living in Germany
  • Participant is able to communicate in German language
  • Participant is able to use digital tools and have access to an internet-capable device

Exclusion criteria

  • A patient will be excluded if she is participating in clinical trials.

Eligibility wording paraphrased from the public record. View the full criteria on ClinicalTrials.gov before contacting a site.

Where it’s happening

CityState / RegionFacilitySite status
Berlin Site DE49001 Unknown

Status & timeline

  • Overall status: Active, not recruiting
  • Study type: Observational
  • Phase: N/A
  • Start date: 2024-10-29
  • Primary completion: 2026-07-31
  • Last update posted: 2026-03-06
  • First posted: 2026-03-06

Lead sponsor: Astellas Pharma Europe Ltd. (Industry)

For trial site contact information, use the official record at ClinicalTrials.gov. Contact details change frequently and the public record is the source of truth.

Outcome measures

Primary outcomes

  • Percentage of participants reporting improvement in hot flushes/night sweats measured by Patient Global Impression of Change of VMS (PGI-C VMS) (Week 24)
    The PGI-C VMS evaluates patient perceived change in hot flashes/night sweats from the initiation of treatment. Ratings range from (1) much better to (7) much worse. A response of "moderately better" or "much better" would be an improvement.

If you’re reading this trial because you have menopause symptoms now, you don’t have to wait for a trial to access evidence-based care. ClearedRx prescribes the same FDA-approved and compounded HRT products that have been studied in trials like this one for decades.

Treatments

What ClearedRx prescribes

10 HRT formulations: patches, tablets, gels, creams, and a non-hormonal SSRI option.

 Symptoms

Menopause symptoms guide

Hot flashes, night sweats, vaginal dryness, mood changes — what each symptom signals.

 Get started

See if HRT is right for you

3-minute intake. A board-certified MD reviews and recommends a route & dose within 24 hours.

 More trials

Browse all menopause trials

Other clinical trials studying menopause, HRT, and related conditions, indexed by NCT ID.

Important. Information from ClinicalTrials.gov as of May 8, 2026. Trial details (status, sites, contacts, eligibility, outcomes) change frequently — always check the official record at https://clinicaltrials.gov/study/NCT07455812 before contacting a site.

ClearedRx is not affiliated with this trial or its sponsor. We index public-domain ClinicalTrials.gov records to help patients find evidence-based context for menopause care decisions. ClearedRx itself is a telehealth menopause/HRT brand — we do not enroll patients in trials.